DISPOSABLE BIOPSY FORCEPS FB-241KRecalls & reported problems
Olympus Medical Systems Corp. · DISPOSABLE BIOPSY FORCEPS · Class 1
- Adverse event reports
- 3
- Deaths reported
- 0
- Injuries reported
- 3
- Recalls naming it
- 0
Summary
The FDA's MAUDE database contains 3 adverse event reports that list this exact device (DI 04953170158087), received between Nov 15, 2020 and Sep 15, 2022 — classified as 3 injuries.
Reports come from manufacturers, hospitals and patients and are not verified by the FDA. A report does not prove the device caused the event, and counts can't be used to compare devices or estimate failure rates. How this data works · Data updated Oct 13, 2026.
Most reported problems
Device problems
- Adverse Event Without Identified Device or Use Problem3
Patient problems
- Hemoptysis2
- Pneumonia2
- Pneumothorax2
- Respiratory Failure2
- Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available1
- Hematoma1
Recent adverse event reports
The 3 most recent of 3 reports, in the reporter's own words as published by the FDA.
InjurySep 15, 2022Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
OLYMPUS REVIEWED THE FOLLOWING LITERATURE TITLED "IMPROVED DIAGNOSTIC YIELD AND SPECIMEN QUALITY WITH ENDOBRONCHIAL ULTRASOUND-GUIDED FORCEPS BIOPSIES: A RETROSPECTIVE ANALYSIS." BACKGROUND. ENDOBRONCHIAL ULTRASOUND (EBUS) TRANSBRONCHIAL NEEDLE ASPIRATION (TBNA) HAS A HIGH DIAGNOSTIC YIELD WHEN EVALUATING MEDIASTINAL AND HILAR LYMPHADENOPATHY (LAD). HAVING PREVIOUSLY DEMONSTRATED THE SAFETY OF EBUS-GUIDED CAUTERY-ASSISTED TRANSBRONCHIAL NODAL FORCEPS BIOPSY (CA-TBFB), WE REPORT DISEASE-SPECIFIC IMPROVEMENTS IN DIAGNOSTIC YIELD AND TISSUE ACQUISITION WHEN SUPPLEMENTING THE EBUS-TBNA¿BASED STANDARD OF CARE (SOC)WITH CA-TBFB. METHODS. WE RETROSPECTIVELY REVIEWED 213 PATIENTS WHO SEQUENTIALLY UNDERWENT SOC AND CA-TBFB DURING THE SAME PROCEDURE. WE DETERMINED 3 CLINICAL SCENARIOS OF INTEREST BASED ON PREPROCEDURAL IMAGING: ISOLATED MEDIASTINAL/HILAR LAD, LAD ASSOCIATED WITH A NODULE OR MASS SUSPICIOUS FOR MALIGNANCY, AND LAD ASSOCIATED WITH PARENCHYMAL FINDINGS SUGGESTIVE OF SARCOIDOSIS. USING VALIDATED METHODS, WE ASSESSED DIAGNOSTIC YIELD ON A PER-PATIENT BASIS AND SPECIMEN QUALITY ON A PER-NODE BASIS ON THE 136 PATIENTS MEETING DIAGNOSTIC CRITERIA. RESULTS. ADMINISTRATION OF DISEASE-
Patient problems: Hemoptysis; Pneumonia; Pneumothorax; Respiratory Failure
MAUDE report 15429337 ↗InjurySep 15, 2022Adverse Event Without Identified Device or Use Problem
OLYMPUS REVIEWED THE FOLLOWING LITERATURE TITLED "IMPROVED DIAGNOSTIC YIELD AND SPECIMEN QUALITY WITH ENDOBRONCHIAL ULTRASOUND-GUIDED FORCEPS BIOPSIES: A RETROSPECTIVE ANALYSIS." BACKGROUND. ENDOBRONCHIAL ULTRASOUND (EBUS) TRANSBRONCHIAL NEEDLE ASPIRATION (TBNA) HAS A HIGH DIAGNOSTIC YIELD WHEN EVALUATING MEDIASTINAL AND HILAR LYMPHADENOPATHY (LAD). HAVING PREVIOUSLY DEMONSTRATED THE SAFETY OF EBUS-GUIDED CAUTERY-ASSISTED TRANSBRONCHIAL NODAL FORCEPS BIOPSY (CA-TBFB), WE REPORT DISEASE-SPECIFIC IMPROVEMENTS IN DIAGNOSTIC YIELD AND TISSUE ACQUISITION WHEN SUPPLEMENTING THE EBUS-TBNA¿BASED STANDARD OF CARE (SOC)WITH CA-TBFB. METHODS. WE RETROSPECTIVELY REVIEWED 213 PATIENTS WHO SEQUENTIALLY UNDERWENT SOC AND CA-TBFB DURING THE SAME PROCEDURE. WE DETERMINED 3 CLINICAL SCENARIOS OF INTEREST BASED ON PREPROCEDURAL IMAGING: ISOLATED MEDIASTINAL/HILAR LAD, LAD ASSOCIATED WITH A NODULE OR MASS SUSPICIOUS FOR MALIGNANCY, AND LAD ASSOCIATED WITH PARENCHYMAL FINDINGS SUGGESTIVE OF SARCOIDOSIS. USING VALIDATED METHODS, WE ASSESSED DIAGNOSTIC YIELD ON A PER-PATIENT BASIS AND SPECIMEN QUALITY ON A PER-NODE BASIS ON THE 136 PATIENTS MEETING DIAGNOSTIC CRITERIA. RESULTS. ADMINISTRATION OF DISEASE-
Patient problems: Appropriate Clinical Signs, Symptoms and Conditions Term/Code Not Available; Hemoptysis; Pneumonia; Pneumothorax; Respiratory Failure
MAUDE report 15428134 ↗InjuryNov 15, 2020Adverse Event Without Identified Device or Use Problem; Adverse Event Without Identified Device or Use Problem
WE RECEIVED THE FOLLOWING REPORT. *WHEN THE ENDOSCOPY WAS PERFORMED, THE BIOPSIES LED HEMORRHAGE WHILE THE PATIENT'S MUCOUS MEMBRANE WAS HEALTHY WITH NO ANTICOAGULANT TREATMENT. ONE OF THE HEMORRHAGIC BIOPSIES RESULTED IN AN OVAL HEMATOMA OF 12MM. THE PATIENT WAS DISCHARGED ONCE, THEN ADMITTED TO THE EMERGENCY ROOM IN THE EVENING OF THE DAY FOR (B)(6). THE PATIENT IS STILL HOSPITALIZED. IT IS UNCLEAR IF THE BIOPSY FORCEPS CONTRIBUTED TO THESE EVENTS.
Patient problems: Hematoma
MAUDE report 10841641 ↗
Other Forceps, Biopsy, Non-Electric devices
- Radial Jaw 4 M00513410Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall24 reports
- Radial Jaw 4 M00513330Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall19 reports
- Radial Jaw 4 M00513400Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall16 reports
- NA 8736685Richard Wolf GmbH · FORCEPS, BIOPSY, NON-ELECTRIC1 recall15 reports
- NA 828051Richard Wolf GmbH · FORCEPS, BIOPSY, NON-ELECTRIC1 recall6 reports
- Radial Jaw 4 M00513320Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall3 reports
- Radial Jaw 4 M00513360Boston Scientific Corporation · FORCEPS, BIOPSY, NON-ELECTRIC1 recall2 reports
- NA 8735685Richard Wolf GmbH · FORCEPS, BIOPSY, NON-ELECTRIC1 recall1 report
Sources: FDA GUDID, MAUDE and Medical Device Recalls via openFDA. openFDA data is not validated for clinical or regulatory use.